Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis

Abstract

In view of the poor outcomes associated with mucormycosis in patients with haematologic malignancies (HM) and haematopoietic cell transplant recipients, antifungal combinations are frequently used, yet the value of such strategy remains unclear. We reviewed the records of HM patients treated for mucormycosis from 1994 to 2014. The primary outcome was 6-week mortality after treatment initiation. Of the 106 patients identified, 44% received monotherapy and 56% received combination treatment as initial therapy. Six-week mortality was associated with disseminated mucormycosis (p 0.018), active malignancy (p <0.01), higher Acute Physiology and Chronic Health Evaluation (APACHE) II scores (p <0.001), neutropenia (p 0.049), lymphopenia (p 0.0003) and intensive care unit (ICU) admission at diagnosis (p 0.0001). Survivors were more likely to have localized mucormycosis (p <0.01) and to receive hyperbaric oxygen therapy (p 0.02). There were no differences in mortality between monotherapy and combination treatment groups (43% vs. 41%; p 0.85). In multivariate analysis, lymphopenia (odds ratio (OR), 5.5; 95% confidence interval (CI), 1.9-15.9; p 0.002) and ICU admission at diagnosis (OR, 8.2; 95% CI, 2.3-29.2; p 0.001) were associated with increased mortality. Localized mucormycosis was associated with better outcome (OR, 0.06; 95% CI, 0.01-0.6; p 0.019). Initial combination treatment had no impact on mortality, even after propensity score adjustment (OR, 0.8; 95% CI, 0.3-2.4; p 0.69). A weighted mortality risk score was then calculated for each patient based on the factors independently associated with mortality and baseline APACHE II score. In the low-risk group (n = 49), 13% of monotherapy versus 15% of combination therapy patients died within 6 weeks (p >0.99). In the high-risk group (n = 57), 71% of monotherapy versus 61% of combination therapy patients died within 6 weeks (p 0.42). With the current status of mucormycosis diagnosis, there was no difference in mortality in HM patients, whether they received monotherapy or combination treatment as initial therapy. Earlier diagnosis and immune reconstitution are unmet needs to affect outcomes.

Mucormycosis diagnosed during induction chemotherapy in five pediatric patients with acute lymphoblastic leukemia

“…All of the patients in our series were initially treated with LAmB and surgical debridement. The use of combination antifungals is controversial, and there are no strong data to support this practice . In fact, there are some data that support combination therapy is associated with increased risk of adverse events .…”

New facets of antifungal therapy

“…Kyvernitakis et al reviewed charts of 106 patients with hematologic malignancy and mucormycosis and found no difference in mortality 6 weeks after therapy between monotherapy and combination therapy. 117 In contrast, Reed et al reviewed the charts of 41 patients with mucormycosis; 34% of these patients had malignancy, 10% had organ transplantation, and 83% had diabetes mellitus. In this group of patients, they found that treatment was successful 30 d after hospital discharge in 100% of patients given combination therapy vs. 45% of patients on monotherapy.…”

Quantifying guideline adherence in mucormycosis management using the EQUAL score

“…Three of 27 patients (11.1%) died within seven days after diagnosis, eight within the first months—accounting for a total mortality of 48.1%. This is in accordance with previously reported studies showing 44% to 72.2% …”